Lung cancer is a leading cause of cancer-related mortality worldwide, and is classically
divided into two major histological subtypes: non-small-cell lung cancer (NSCLC) and small …

Approximately one third of all lung cancer patients in East Asia are never-smokers.
Furthermore, the proportion of lung cancer in never smokers (LCINS) has been increasing …

According to rapid development of chemotherapy in advanced non-small cell lung cancer
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually …

Background The therapeutic efficacy of epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs) in advanced EGFR-mutant lung squamous cell carcinoma (SCC) …

EGFR mutation frequencies in unselected Caucasian populations are unknown. This study
assesses the prevalence of EGFR mutations in an unselected population‐based cohort, and …

Introduction Squamous-cell carcinoma (SCC) of the lung represents around 20% of non-
small cell lung cancers. Although activating mutations of EGFR are rare in this subtype, its …

The management of advanced stage nonsmall cell lung cancer (NSCLC) has been altered
by the recognition of histology-based treatment and the use of targeted therapy. Whilst …

Adenocarcinoma (AD) and squamous cell carcinoma (SCC) are both classified as major
forms of non-small cell lung cancer, but differences in clinical prognoses and molecular …

The empirical criteria for defining a clinical subtype of lung cancer are gradually transiting
from histopathology to genetic variations in driver genes. Targeting these driver mutations …

Context.—Lung tumors are histologically heterogeneous, but classification of lung
carcinoma has prognostic impact and increasingly, specific molecular correlates. Objective …